


Lead Indication Target	Candidate	Research	Hit	Lead	Pre-clinic	Phase I	Phase II	Sponsor / Licensee	
<b>PDAC</b> Neurotensin receptor	IPN-01087								
	3BP-227 NN								
<b>Solid Tumors</b> Fibroblast Activation Protein α (FAP)	FAP-2286							 US, RoW (ex Europe)	 Europe
	FAP-2287								
<b>Neuroendocrine Tumors</b> GIP receptor	3B-401								
	3B-402								
<b>ccRCC</b> CAIX	Debio 0228								
	3B-301								
<b>Solid Tumors</b>	3B-501								
	3B-502								

 THERAPEUTIC RADIOPHARMACEUTICAL  
 SPECT OR PET IMAGING AGENT